Profitability and growth in the US remain soft; sluggish sales in India add to concerns
FDI in the sector is a contentious issue as concerns have been raised over some M&As of Indian pharma companies by foreign giants
With most concerns priced in, investors may start bottom-fishing as valuations look reasonable
Price hikes, new launches help sector maintain average of 12.9% since April 2015, but was lower against February 2015 growth of 18.9%
Files a PIL suit in the Supreme Court accusing them of failing to enforce rules on drug safety
She said there is confusion and chaos in the pharma sector due to multi-ministerial control